Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial

Roche said patients lost 22.7% of body weight in a mid-stage trial of its dual-acting experimental obesity drug. More than a quarter of patients on the highest dose achieved at least 30% weight loss, a strong efficacy signal for the program. The update is favorable for Roche’s obesity pipeline, though it remains early-stage and is unlikely to move the broader market.

Analysis

Roche said patients lost 22.7% of body weight in a mid-stage trial of its dual-acting experimental obesity drug. More than a quarter of patients on the highest dose achieved at least 30% weight loss, a strong efficacy signal for the program. The update is favorable for Roche’s obesity pipeline, though it remains early-stage and is unlikely to move the broader market.